WCN’21 abstract submission is now closed.
Abstract authors will be notified of acceptance January 11, 2021.
Abstracts should focus on all aspects of nephrology, the treatment of renal disease or the scientific background relating to the study of the kidney.
Canadian abstract authors:
All Canadian abstracts submitted to the WCN’21 Congress in April, will also be considered for presentation at the CSN AGM in May. The CSN AGM will not have a separate abstract submission this year.
How will your abstracts be presented?
Accepted abstracts will be presented as an e-poster on the virtual congress platform. The e-poster area will be accessible 24/7 during the congress and on-demand for weeks after the actual congress dates. Poster presenters have the opportunity to interact with participants through Q&A and may add a brief oral communication to their presented poster. All accepted abstracts will be published in Kidney International Reports.
Presenting authors must register for the congress by February 10, 2021 to have their abstract published as described above and to have a e-poster presentation at the congress. Please note, the abstract fee is not deducted from the registration fee and having an accepted abstract does not waive any registration fee.
Check out the instructions on how to complete your online application below, and then read on for the abstract categories.
- Character count: You may use up to 3,400 characters. Spaces are included in the character count (tables and graphs do not count as characters if inserted as an image). Abstract authors/co-authors’ names and affiliations, and keywords do not count towards the 3,400 character allowance.
- Abstracts are structured: Introduction, methods, results, conclusion. Tables, graphs, and pictures may be included (tables and graphs do not count as characters if inserted as an image).
- Images must be in JPEG or PNG format (uploaded images cannot exceed 640w x 480h pixels and 1,5 Megabytes).
- Case reports that present novel hypotheses, pathologies, treatments, or ethical issues are welcome. However, they are only likely to be selected if the originality is highlighted effectively.
- Submitted abstracts must describe unpublished work, which is not already in press and which is not awaiting possible acceptance by any other society/journal. Encore abstracts are not accepted.
- The maximum number of abstract co-authors that can be listed in an abstract is 15.
- Please check carefully for typographical errors, misspellings, poor hyphenation, etc. Please check that your abstract title is correct.
- COVID-19: Because many events have been canceled or made virtual due to the COVID-19 pandemic, abstracts submitted to other meetings in 2020 will exceptionally be accepted. However, abstract authors must declare this at the end of the abstract in the following way: This abstract was also submitted for the (insert meeting title) congress. By submitting the abstract to WCN’21, abstract authors declare that re-submitting the abstract is permitted by the organizers of the previous meeting.
- WCN is a paperless congress. Accepted abstracts will be published electronically in the searchable databases of WCN’21 and Kidney International Reports. No printed abstract book will be produced.
- Presenting authors must register for the congress by February 10, 2021, to have their abstract published as described above and to have a e-poster presentation at the congress. If you have submitted an abstract for the congress, the same congress profile (login identity) must be used to register for the event.
- A non-refundable handling fee of 40 USD is charged per abstract that is submitted. The handling fee must be paid by credit card (American Express, MasterCard, or Visa) at the time of submitting the abstract. Payment by bank transfer is not possible. Abstract handling fees are waived ONLY for submitters from low-income countries as defined by the ISN Low Income list which is based on the World Bank list dated June 2020. Click here to view the list. The handling fee for late-breaking clinical trials abstracts is 100 USD and is not waived for submitters from low-income countries. Abstract invoice will be available in the submitting author’s congress profile (section “My Congress Documents”) after payment.
- If the presenting author is unable to present the abstract, a co-author can take their place, as long as they are registered for the congress. The presenting author must inform the congress secretariat of the change at firstname.lastname@example.org, no later than February 10, 2021. If selected abstract presenters fail to register by February 10, 2021, no abstract will be published, and there will be no e-poster presentation at the congress.
- Once submitted, abstracts cannot be changed or withdrawn.
- All copyrights are assigned to ISN.
- All submitted abstracts will be considered for an e-poster presentation.
- ISN Young Nephrologists Awards: For two outstanding presenting authors under the age of 40, the ISN contributes toward registration fees to attend the congress. Each winner will have a ten-minute oral abstract presentation during a session at the congress. Application for the award is possible only during the online abstract submission process.
- Organ trafficking and tourism ethics compliance: scientific studies and clinical activities must be performed in keeping with the ethical principles outlined in the Declaration of Istanbul on Organ Trafficking and Transplant Tourism. By submitting an abstract for WCN’21, you state that you have not violated any aspect of the Declaration or associated consensus statements on live donation and research on human subjects.
After your submission has been submitted, you will receive a confirmation email within two business days. If the email doesn’t appear, please check your spam folder.
If you submitted your abstract on the last day of submission (November 30, 2020) and do not receive confirmation within 48 hours, please email: email@example.com to make sure your abstract has been received.
Abstract authors will be notified of acceptance January 11, 2021.
Explore abstract categories below:
Acute kidney injury, electrolytes, and acid-base disorders, tropical diseases, RPGN, and pregnancy-related renal disease
- Acute kidney injury, clinical drugs, AKI-CKD continuum
- Acute kidney injury – mechanisms, experimental models, and biomarkers
- Acid-base and electrolyte abnormalities in kidney disease
- Experimental models – glomerulonephritis
- Clinical glomerulonephritis
- Tropical kidney diseases (viral nephropathies, TB, schistosomiasis, malaria, leptospirosis, animal venoms)
- Kidney in pregnancy and post-partum
- Other AKIs
Chronic kidney disease, hypertension, diabetes, and CVD
- Chronic kidney disease diagnosis, classification, and progression
- Chronic kidney disease complications (CVD, hypertension, anemia, BMD, nutrition, infection)
- Epidemiology, outcomes, and health service research related to CKD or its complications
- Diabetic kidney disease, drugs, and treatments
- Chronic kidney disease, experimental models, biomarkers, precision medicine
- Vascular biology and endothelial function
- Physiology of tubular function and tubulointerstitial kidney disease
- Essential hypertension and renovascular kidney disease
- Special challenges in the burden and management of CKD in developing countries
- Genetics and epigenetics (including common and rare genetic diseases)
- Inflammation, fibrosis, matrix biology, and oxidative stress
- Urologic disorders – stones, nephrocalcinosis
- Nephrotic syndrome
- Other CKDs
Kidney Failure (including dialysis, transplantation, and conservative care)
- Epidemiology, outcomes, and health services research in dialysis
- Haemodialysis, haemodiafiltration, and vascular access
- Peritoneal dialysis
- Bioethics, supportive/palliative care, and quality of life with kidney failure
- Kidney transplantation and transplant immunology
- Other kidney failure diseases
- Social media
- Online learning
Abstract platform supported by